Belimumab is a medication used to treat systemic lupus erythematosus (SLE) [1]. It is a biologic therapy that works by inhibiting B-lymphocyte stimulator (BLyS), a protein that plays a role in the survival and function of B cells, which are implicated in the autoimmune response in lupus [1][2].
What conditions does belimumab treat?
Belimumab is approved for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy [1]. It has also received approval in some regions for use in pediatric patients aged 5 to 17 years with active, autoantibody-positive SLE [3].
How does belimumab work for lupus?
Belimumab targets B-lymphocyte stimulator (BLyS), also known as BAFF. BLyS is a cytokine that promotes the survival and maturation of B cells. In individuals with SLE, an overabundance of BLyS can contribute to the persistence of autoreactive B cells, leading to the production of autoantibodies and subsequent tissue damage [2][4]. By binding to BLyS, belimumab prevents it from activating B cells, thereby reducing the number of B cells and the production of autoantibodies [2].
When did belimumab become available?
Belimumab was first approved by the U.S. Food and Drug Administration (FDA) in 2011 [1].
Who manufactures belimumab?
Belimumab is manufactured by GlaxoSmithKline (GSK) [5].
What are the potential side effects of belimumab?
Common side effects associated with belimumab treatment include nausea, diarrhea, fever, rash, and insomnia [1]. More serious potential side effects, though less common, can include infections, depression, and certain types of cancer [1]. Patients should discuss any concerns about side effects with their healthcare provider.
How does belimumab compare to other lupus treatments?
Belimumab represents a significant advancement in lupus treatment as one of the first targeted biologic therapies approved for SLE [2]. Unlike traditional immunosuppressants that broadly suppress the immune system, belimumab specifically targets the B-cell pathway involved in lupus pathogenesis. Other treatments for SLE can include non-steroidal anti-inflammatory drugs (NSAIDs), antimalarials, corticosteroids, and other immunosuppressants. The choice of treatment depends on the severity and specific manifestations of the disease [6].
What is the patent status of belimumab?
Belimumab is protected by patents, which grant the manufacturer exclusive rights to market the drug for a certain period [7]. Information on specific patent expiry dates and any ongoing patent challenges can be found on specialized drug patent databases, such as DrugPatentWatch.com [7].
Can biosimilars of belimumab be developed?
The development of biosimilar versions of biologic drugs like belimumab is possible once their patent protection expires and regulatory pathways are established [8]. Biosimilars are highly similar to the reference biologic drug, with no clinically meaningful differences in terms of safety, purity, and potency [8]. The introduction of biosimilars can potentially increase market competition and reduce treatment costs.